Skip to main content

Advertisement

SpringerLink
Log in

Expression of chemokine receptor 4 was associated with poor survival in renal cell carcinoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Chemokines and their receptors are known to play important roles in tumor growth and metastasis of many malignancies. Recently, CC chemokine receptor 4 (CCR4) has been described as a prognostic marker in various tumors. However, the possible role of CCR4 in clear cell renal cell carcinoma (ccRCC) has not been well elucidated. In this study, we detected the expression of CCR4 in 53 ccRCC by immunohistochemistry and correlated it with clinicopathological parameters and prognosis. Immunohistochemistry was used to determine the expression of CCR4 in 53 ccRCC and 11 renal contusion tissue specimens. CCR4 expression between carcinoma and normal renal tissues was evaluated by χ 2 test. Correlation between CCR4 and clinicopathological data was tested by χ 2 test. Univariate survival analysis was performed by the Kaplan–Meier method, and differences among the groups were analyzed by the log-rank test. CCR4 expression in ccRCC tissue was significantly higher compared with normal renal tissue samples (χ 2 = 4.392, P = 0.036). CCR4 was correlated with the clinicopathological features including tumor stage (P = 0.009), lymph node metastasis (P = 0.003) and distant metastasis (P = 0.031). Further, CCR4 was the only dependent affecting factor in lymph node metastasis (P = 0.014). Univariate analysis showed that tumor stage, lymph node metastasis, distant metastasis and CCR4 were influential factors for poor prognosis in ccRCC patients; multivariate analysis revealed that CCR4 (P = 0.007) was the only independent risk factor for prognosis. In addition, Kaplan–Meier curve for overall survival (OS) indicated that prognosis was unfavorable for patients who had high CCR4 expression level (P = 0.010). CCR4 was correlated with tumor aggressive behavior in ccRCC. It might be involved in lymph node metastasis and have influence on patients’ OS. Further research is needed to determine the potential of CCR4.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373:1119–32.

    Article  CAS  PubMed  Google Scholar 

  2. Jones J. Libermann TA: genomics of renal cell cancer: the biology behind and the therapy ahead. Clin Cancer Res. 2007;13:685s–92s.

    Article  CAS  PubMed  Google Scholar 

  3. Patil S, Ishill N, Deluca J, et al. Stage migration and increasing proportion of favourable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation. Cancer. 2010;116:347–54.

    Article  PubMed  Google Scholar 

  4. Novara G, Ficarra V, Antonelli A, et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol. 2010;58:588–95.

    Article  PubMed  Google Scholar 

  5. Baggiolini M. Chemokines and leukocyte traffic. Nature. 1998;392:565–8.

    Article  CAS  PubMed  Google Scholar 

  6. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–6.

    Article  CAS  PubMed  Google Scholar 

  7. Wang J, Xi L, Hunt JL, et al. Expression pattern of chemokine receptor 6 (CCR6) and CCR 7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res. 2004;64:1861–6.

    Article  CAS  PubMed  Google Scholar 

  8. Ueda M, Shimada T, Goto Y, et al. Expression of CC-chemokine receptor 7 (CCR7) and CXC -chemokine receptor 4 (CXCR4) in head and neck squamous cell carcinoma. Auris Nasus Larynx. 2010;37:488–95.

    Article  PubMed  Google Scholar 

  9. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2007;449:557–63.

    Article  CAS  Google Scholar 

  10. Imai T, Nagira M, Takagi S, et al. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol. 1999;11:81–8.

    Article  CAS  PubMed  Google Scholar 

  11. Yang YM, Feng AL, Zhou CJ, et al. Aberrant expression of chemokine receptor CCR4 in human gastric cancer contributes to tumor-induced immunosuppression. Cancer Sci. 2011;102:1264–71.

    Article  CAS  PubMed  Google Scholar 

  12. Li JY, Ou ZL, Yu SJ, et al. The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer. Breast Cancer Res Treat. 2012;131(3):837–48.

    Article  CAS  PubMed  Google Scholar 

  13. Biragyn A, Bodogai M, Olkhanud PB, et al. Inhibition of lung metastasis by chemokine CCL17-mediated in vivo silencing of genes in CCR4 + Tregs. J Immunother. 2013;36:258–67.

    Article  CAS  PubMed  Google Scholar 

  14. Tsujikawa T, Yaguchi T, Ohmura G, et al. Autocrine and paracrine loops between cancer cells and macrophages promote lymph node metastasis via CCR4/CCL22 in head and neck squamous cell carcinoma. Int J Cancer. 2013;132:2755–66.

    Article  CAS  PubMed  Google Scholar 

  15. Zhang T, Rexiati M, SaiMaiti W, et al. Establishment of serum protein fingerprint patterns of Uygur renal cancer in Xinjiang. Chin J Urol. 2012;34(3):184–7.

    Google Scholar 

  16. Yu H, Huang X, Liu X, et al. Regulatory T cells and plasmacytoid dendritic cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic goiter. Endocrine. 2013;44(1):172–81.

    Article  CAS  PubMed  Google Scholar 

  17. Deng B, Zhu JM, Wang Y, et al. Intratumor hypoxia promotes immune tolerance by inducing regulatory T cells via TGF-β1 in gastric cancer. PLoS One. 2013;8(5):e63777.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Schmidt HH, Ge Y, Hartmann FJ, et al. HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients. Oncoimmunology. 2013;2(6):e24962.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Zhang S, Yong LK, Li D, et al. Mesothelin virus-like particle immunization controls pancreatic cancer growth through CD8+ T cell induction and reduction in the frequency of CD4+ foxp3+ ICOS− regulatory T cells. PLoS One. 2013;8(7):e68303.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Hiroyoshi N, Shimon S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127(4):759–67.

    Google Scholar 

  21. Ishida T, Ueda R. Immunopathogenesis of lymphoma: focus on CCR4. Cancer Sci. 2011;102(1):44–50.

    Article  CAS  PubMed  Google Scholar 

  22. Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia–lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28:1591–8.

    Article  CAS  PubMed  Google Scholar 

  23. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837–42.

    Article  CAS  PubMed  Google Scholar 

  24. Pere H, Montier Y, Bayry J, et al. A CCR4 antagonist combined with vaccine s induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood. 2011;118:4853–62.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This project was financially supported by the National Natural Science Foundation of China (81060210).

Conflict of interest

No potential conflicts of interest were disclosed.

Author information

Authors and Affiliations

  1. Department of Urology, The First Affiliated Hospital of XinJiang Medical University, Ürümqi, China

    Qiang Liu, Mulati Rexiati, Wen-Guang Wang, Baihetiya Azhati, Weilijiang SaiMaiti & Yu-Jie Wang

  2. Department of Cancer Center, The First Affiliated Hospital of XinJiang Medical University, Ürümqi, China

    Ying Yang

Authors
  1. Qiang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mulati Rexiati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ying Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wen-Guang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Baihetiya Azhati
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Weilijiang SaiMaiti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yu-Jie Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yu-Jie Wang.

Additional information

Qiang Liu and Ying Yang have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, Q., Rexiati, M., Yang, Y. et al. Expression of chemokine receptor 4 was associated with poor survival in renal cell carcinoma. Med Oncol 31, 882 (2014). https://doi.org/10.1007/s12032-014-0882-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0882-y

Keywords

Search

Navigation